FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113100908> ?p ?o ?g. }

• W2113100908 endingPage "2342" @default.
• W2113100908 startingPage "2331" @default.
• W2113100908 abstract "Neuroimmunophilin ligands are a class of compounds that hold great promise for the treatment of nerve injuries and neurological disease. In contrast to neurotrophins (e.g., nerve growth factor), these compounds readily cross the blood-brain barrier, being orally effective in a variety of animal models of ischaemia, traumatic nerve injury and human neurodegenerative disorders. A further distinction is that neuroimmunophilin ligands act via unique receptors that are unrelated to the classical neurotrophic receptors (e.g., trk), making it unlikely that clinical trials will encounter the same difficulties found with the neurotrophins. Another advantage is that two neuroimmunophilin ligands (cyclosporin A and FK-506) have already been used in humans (as immunosuppressant drugs). Whereas both cyclosporin A and FK-506 demonstrate neuroprotective actions, only FK-506 and its derivatives have been clearly shown to exhibit significant neuroregenerative activity. Accordingly, the neuroprotective and neuroregenerative properties seem to arise via different mechanisms. Furthermore, the neuroregenerative property does not involve calcineurin inhibition (essential for immunosuppression). This is important since most of the limiting side effects produced by these drugs arise via calcineurin inhibition. A major breakthrough for the development of this class of compounds for the treatment of human neurological disorders was the ability to separate the neuroregenerative property of FK-506 from its immunosuppressant action via the development of non-immunosuppressant (non-calcineurin inhibiting) derivatives. Further studies revealed that different receptor subtypes, or FK-506-binding proteins (FKBPs), mediate immunosuppression and nerve regeneration (FKBP-12 and FKBP-52, respectively, the latter being a component of steroid receptor complexes). Thus, steroid receptor chaperone proteins represent novel targets for future drug development of novel classes of compounds for the treatment of a variety of human neurological disorders, including traumatic injury (e.g., peripheral nerve and spinal cord), chemical exposure (e.g., vinca alkaloids, Taxol) and neurodegenerative disease (e.g. , diabetic neuropathy and Parkinson's disease)." @default.
• W2113100908 created "2016-06-24" @default.
• W2113100908 creator A5032750738 @default.
• W2113100908 date "2000-10-01" @default.
• W2113100908 modified "2023-10-16" @default.
• W2113100908 title "Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders" @default.
• W2113100908 cites W1511792975 @default.
• W2113100908 cites W1522775437 @default.
• W2113100908 cites W1528505919 @default.
• W2113100908 cites W1657897383 @default.
• W2113100908 cites W1834422411 @default.
• W2113100908 cites W1965388311 @default.
• W2113100908 cites W1968671288 @default.
• W2113100908 cites W1969612832 @default.
• W2113100908 cites W1974892577 @default.
• W2113100908 cites W1976441097 @default.
• W2113100908 cites W1978197119 @default.
• W2113100908 cites W1978559408 @default.
• W2113100908 cites W1985971810 @default.
• W2113100908 cites W1986094270 @default.
• W2113100908 cites W1990918954 @default.
• W2113100908 cites W1991893050 @default.
• W2113100908 cites W2003031313 @default.
• W2113100908 cites W2004391423 @default.
• W2113100908 cites W2007749506 @default.
• W2113100908 cites W2009032298 @default.
• W2113100908 cites W2009058877 @default.
• W2113100908 cites W2009065142 @default.
• W2113100908 cites W2016854943 @default.
• W2113100908 cites W2020597127 @default.
• W2113100908 cites W2023131407 @default.
• W2113100908 cites W2028547922 @default.
• W2113100908 cites W2031705137 @default.
• W2113100908 cites W2036539375 @default.
• W2113100908 cites W2039721791 @default.
• W2113100908 cites W2041561339 @default.
• W2113100908 cites W2042740099 @default.
• W2113100908 cites W2043897928 @default.
• W2113100908 cites W2055183364 @default.
• W2113100908 cites W2057476516 @default.
• W2113100908 cites W2057767803 @default.
• W2113100908 cites W2060090607 @default.
• W2113100908 cites W2060733653 @default.
• W2113100908 cites W2062805042 @default.
• W2113100908 cites W2067957091 @default.
• W2113100908 cites W2070564946 @default.
• W2113100908 cites W2074243828 @default.
• W2113100908 cites W2075702813 @default.
• W2113100908 cites W2076384379 @default.
• W2113100908 cites W2076811542 @default.
• W2113100908 cites W2077769042 @default.
• W2113100908 cites W2082215172 @default.
• W2113100908 cites W2084402494 @default.
• W2113100908 cites W2094893926 @default.
• W2113100908 cites W2095035055 @default.
• W2113100908 cites W2098257766 @default.
• W2113100908 cites W2100789276 @default.
• W2113100908 cites W2101408825 @default.
• W2113100908 cites W2101508627 @default.
• W2113100908 cites W2101996466 @default.
• W2113100908 cites W2110715762 @default.
• W2113100908 cites W2121108041 @default.
• W2113100908 cites W2126706634 @default.
• W2113100908 cites W2135128039 @default.
• W2113100908 cites W2137341857 @default.
• W2113100908 cites W2143302994 @default.
• W2113100908 cites W2151601807 @default.
• W2113100908 cites W2153842250 @default.
• W2113100908 cites W2162812410 @default.
• W2113100908 cites W2167839140 @default.
• W2113100908 cites W2419411847 @default.
• W2113100908 cites W3209643541 @default.
• W2113100908 cites W80326990 @default.
• W2113100908 doi "https://doi.org/10.1517/13543784.9.10.2331" @default.
• W2113100908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11060810" @default.
• W2113100908 hasPublicationYear "2000" @default.
• W2113100908 type Work @default.
• W2113100908 sameAs 2113100908 @default.
• W2113100908 citedByCount "132" @default.
• W2113100908 countsByYear W21131009082012 @default.
• W2113100908 countsByYear W21131009082013 @default.
• W2113100908 countsByYear W21131009082014 @default.
• W2113100908 countsByYear W21131009082015 @default.
• W2113100908 countsByYear W21131009082016 @default.
• W2113100908 countsByYear W21131009082017 @default.
• W2113100908 countsByYear W21131009082018 @default.
• W2113100908 countsByYear W21131009082019 @default.
• W2113100908 countsByYear W21131009082020 @default.
• W2113100908 countsByYear W21131009082023 @default.
• W2113100908 crossrefType "journal-article" @default.
• W2113100908 hasAuthorship W2113100908A5032750738 @default.
• W2113100908 hasConcept C126322002 @default.
• W2113100908 hasConcept C128057223 @default.
• W2113100908 hasConcept C134139212 @default.
• W2113100908 hasConcept C160539049 @default.
• W2113100908 hasConcept C169760540 @default.
• W2113100908 hasConcept C170493617 @default.
• W2113100908 hasConcept C203014093 @default.

• next